« Exercise and Vitamins: Now, Wait A Minute. . . |
| Goldman Sachs: Out Of the Drug Funding Business Already? »
May 13, 2009
Takeda Evaluating Scientists on "Quality"?
This may be just the Japanese equivalent of HR-speak, but I would like to know what it means:
Takeda Pharmaceutical Co., Asia’s biggest drugmaker, will change its research and development policy by providing compensation to scientists based on the quality of their work.
“We focused too much on the quantity and speed of research and development, which didn’t necessarily bring results,” company President Yasuchika Hasegawa told reporters at a briefing in Tokyo. “I want to change everyone’s mindset.”
The problem is, evaluating the quality of individual scientific performance is notoriously difficult. Or was the problem that Takeda was too focused on the numbers, and has decided to back off on that? (I think I could be behind that initiative). Perhaps some one at Millennium could comment on whether they've heard anything about this?
+ TrackBacks (0) | Category: Who Discovers and Why
POST A COMMENT
- RELATED ENTRIES
- The Smallest Drugs
- Life Is Too Short For Some Journal Feeds
- A New Look at Phenotypic Screening
- Small Molecules - Really, Really Small
- InterMune Bought
- Citable Garbage
- The Palbociclib Saga: Or Why We Need a Lot of Drug Companies
- Why Not Bromine?